Back to Search
Start Over
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
- Source :
- OncoImmunology, Vol 8, Iss 4 (2019), Oncoimmunology
- Publication Year :
- 2019
- Publisher :
- Taylor & Francis Group, 2019.
-
Abstract
- In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy increased PD-1/PD-L1 expression and PD-1 blockade further enhanced tumor regression. Further clinical development of this strategy for treating melanomas warranted.
- Subjects :
- 0301 basic medicine
lcsh:Immunologic diseases. Allergy
programmed cell death 1 (pd-1)
medicine.medical_treatment
Immunology
mek inhibition
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
melanoma
Immunology and Allergy
Medicine
Author's View
oncolytic virus
business.industry
Melanoma
Translational medicine
Cancer
Immunotherapy
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Immune checkpoint
Oncolytic virus
Blockade
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Cancer research
immunotherapy
business
Talimogene laherparepvec
lcsh:RC581-607
Subjects
Details
- Language :
- English
- Volume :
- 8
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- OncoImmunology
- Accession number :
- edsair.doi.dedup.....754f12542bfb539d166d5a856b41c29d